Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
06/18/2017 06/19/2017 06/20/2017 06/21/2017 06/22/2017 Date
10970(c) 11050(c) 11080(c) 11140(c) 11120(c) Last
326 645 356 893 363 651 547 182 419 599 Volume
-1.70% +0.73% +0.27% +0.54% -0.18% Change
More quotes
Financials ($)
Sales 2017 23 489 M
EBIT 2017 7 190 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,79%
Sales 2018 23 103 M
EBIT 2018 7 021 M
Net income 2018 4 202 M
Debt 2018 21 087 M
Yield 2018 3,85%
P/E ratio 2017 8,06
P/E ratio 2018 7,80
EV / Sales2017 2,47x
EV / Sales2018 2,31x
Capitalization 32 234 M
More Financials
Company
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services.It operates through the following two segments: Generic and Specialty Medicine.The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including... 
Sector
Pharmaceuticals
Calendar
07/13 | 03:30pmShareholder meeting
More about the company
Surperformance© ratings of Teva Pharmaceutical Indust
Trading Rating : Investor Rating :
More Ratings
Latest news on TEVA PHARMACEUTICAL INDUST
06/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Pataday® ..
06/22 TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of Generic Zetia® in the Unite..
06/22 TEVA PHARMACEUTICAL INDUSTRIES : loses $235m patent trial to GSK
06/19 TEVA PHARMACEUTICAL INDUSTRIES : AbCellera expands research collaboration with T..
06/16 TEVA PHARMACEUTICAL INDUSTRIES : embroiled in Copaxone dosage levels dispute
06/15 TEVA PHARMACEUTICAL INDUSTRIES : Fremanezumab Meets all Primary & Secondary Endp..
06/15 CTI BIOPHARMA : Hikes on Teva Milestone Payment
06/14 TEVA PHARMACEUTICAL INDUSTRIES : launches generic cholesterol treatment
06/14 TEVA PHARMACEUTICAL INDUSTRIES : launches generic allergic eye treatment Pataday..
06/13 TEVA PHARMACEUTICAL INDUSTRIES : launches generic cholesterol treatment
More news
Sector news : Pharmaceuticals - NEC
12:20p China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
06:11aTeva Pharmaceutical Industries Limited downgraded by Vetr Inc. to sell. $31.0.. 
06/22Teva Pharmaceutical Industries : ADRs End Higher; Pharmaceuticals Trade Activ.. 
06/22Teva Pharmaceutical Industries Limited $TEVA PT Set at $38.00 by Royal Bank O.. 
06/21Teva Pharmaceutical Industries Limited $TEVA Shares Sold by Lazard Asset Mana.. 
06/21Teva Pharmaceutical Industries Limited $TEVA Receives Daily News Sentiment Ra.. 
More tweets
Qtime:27
News from SeekingAlpha
06/22 JUNE BUYS : The 16 Stocks Added To My Fund
06/22 Drug stocks rally on GOP draft of healthcare bill
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 FDA aims at removing barriers to generic drug competition
06/21 Put Regeneron On Your Investment Radar In 2017
Advertisement
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-19.23%32 234
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results